The Cytotoxicity and Insecticidal Activity of Extracts from Delphinium formosum Boiss. & Huet

Delphinium species are well-known toxic plants with diterpenoid alkaloid contents. There has been no previous investigation on the cytotoxicity of Delphinium formosum. The extracts of the different parts of D. formosum, an endemic species in Turkey, were investigated for their cytotoxic activity against the human liver carcinoma cell line (HepG2) and primary human umbilical vein endothelial cells (HUVEC). The cytotoxic effects of twelve extracts and subfractions were determined against HepG2 cells using the MTT assay. The only active extract was applied to the HUVEC as a model for healthy cells. Only one of the alkaloidcontaining extracts from the aerial parts was toxic (IC50=244,9 µg/mL against HepG2 and 144,4 µg/mL against HUVEC), while the root extracts were inactive. The results were improbable although it is predicted secondary metabolites, such as diterpene alkaloids (methyllycaconitine, browniine, lycoctonine, avardharidine, antranoyllycoctonine, delsemine A/B and lycoctonine). Based on previous studies in the literature, the cytotoxic plants were also expected to exhibit insecticidal activity. Therefore, the cytotoxic extract of D. formosum was examined for its adulticidal and larvicidal activity against the yellow fever, dengue fever and the Zika virus vector Aedes aegypti L

Pharmaceutical Care Services During the COVID-19 Pandemic in Turkey: Proposal of a Holistic Approach

Community pharmacists, who are among the primary healthcare service providers, are regarded as the closest and most accessible healthcare professionals. Unfortunately, patient counseling, one of the most important pharmacy profession tasks, cannot he performed in exceptional cases, which can endanger patient safety. The coronavirus disease-19 (COVID-19) pandemic process we are facing today is an example of these particular situations in Turkey. Partial curfews imposed within the scope of COVID-19 pandemic measures have also increased problems. Therefore, there is a need for a pharmaceutical care service network that will enable individuals who do nor have aces to pharmacies, who arc in risk groups, or whose mobility is restricted due to pandemic or disaster, to reach their prescribed medicines safely under pharmacist consultancy. In this regard, establishing a pharmaceutical care service network on a scientific and systematic basis may solve the current problems, mostly encountered during the COVID-19 pandemic in Turkey. Designing a network within the framework of vehicle routing and assignment problems is important in ensuring patients' rapid access to prescribed medications and preventing unfair competition among pharmacies

Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects

Favipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration was associated with systemic side effects in susceptible patients. Considering that the pulmonary route could provide a high drug concentration, and a safer application with less absorption into systemic circulation, it was aimed to elucidate whether favipiravir delivered via soft-mist inhaler has any deleterious effects on lung, liver and kidney tissues of healthy rats. Wistar albino rats of both sexes (n = 72) were placed in restrainers, and were given either saline or favipiravir (1, 2.5, 5 or 10 mg/kg in 1 mL saline) by inhalation within 2 min for 5 consecutive days. On the 6th day, electrocardiographic recording was obtained, and cardiac blood and lung tissues were collected. Favipiravir did not alter cardiac rhythm, blood cell counts, serum levels of alanine transaminase, aspartate transaminase, blood urea nitrogen, creatinine, urea or uric acid, and did not cause any significant changes in the pulmonary malondialdehyde, myeloperoxidase activity or antioxidant glutathione levels. Our data revealed that pulmonary use of favipiravir via soft-mist inhaler enables a high local concentration compared to plasma without oxidative lung injury or cardiac or hepatorenal dysfunction

Early effects of low molecular weight heparin therapy with soft-mist inhaler for covid-19-induced hypoxemia: A phase iib trial

© 2021 by the authors. Licensee MDPI, Basel, Switzerland.In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler